These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2554484)

  • 1. [Heparin and its low molecular weight derivatives].
    Aiach M
    Rev Prat; 1989 Oct; 39(22):1973-7. PubMed ID: 2554484
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral treatment with low molecular weight heparin normalizes blood pressure in hypertensive rats.
    Vasdev S; Ford CA; Longerich L; Barrett B; Parai S; Campbell N
    Artery; 1994; 21(1):1-28. PubMed ID: 7980029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anticoagulant and antithrombotic effects of low molecular weight heparin].
    Bashkov GV; Kalishevskaia TM; Bako N
    Biull Eksp Biol Med; 1988 Oct; 106(10):399-402. PubMed ID: 2847825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparin: laboratory properties and clinical evaluation. A review.
    Hirsh J; Levine MN
    Eur J Surg Suppl; 1994; (571):9-22. PubMed ID: 7519092
    [No Abstract]   [Full Text] [Related]  

  • 5. The influence of low molecular weight heparin in combination with dihydroergotamine on experimental thrombosis and haemostasis.
    Bergqvist D; Nilsson B
    Thromb Haemost; 1987 Oct; 58(3):893-5. PubMed ID: 2829377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links.
    Mousa SA
    Semin Thromb Hemost; 2007 Jul; 33(5):524-33. PubMed ID: 17629850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epilogue. Expanded role of low-molecular-weight heparins in hematology and oncology.
    Hoppensteadt DA; Fareed J; Bick RL
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():105-8. PubMed ID: 15085471
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of transplant arteriosclerosis in rat aortic grafts by low molecular weight heparin derivatives.
    Akyürek LM; Funa K; Wanders A; Larsson E; Fellström BC
    Transplantation; 1995 Jun; 59(11):1517-24. PubMed ID: 7778166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
    Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
    Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The treatment of deep venous thrombosis using low-molecular heparin. Swiss Consensus Conference for the Application of Low-molecular Heparin].
    Bachmann F
    Schweiz Med Wochenschr; 1994 Feb; 124(5):169-78. PubMed ID: 8128198
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemistry of heparin and low molecular weight heparin.
    Nielsen JI; Ostergaard P
    Acta Chir Scand Suppl; 1988; 543():52-6. PubMed ID: 2847458
    [No Abstract]   [Full Text] [Related]  

  • 12. The emerging role of low-molecular-weight heparin in cardiovascular medicine.
    Hirsh J; Bates SM
    Prog Cardiovasc Dis; 2000; 42(4):235-46. PubMed ID: 10661777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparin: an anticoagulation therapy option.
    Mege J
    Pa Med; 1999 Dec; 102(12):16, 18. PubMed ID: 10641527
    [No Abstract]   [Full Text] [Related]  

  • 14. A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine.
    Aziz S; Tada Y; Gordon D; McDonald TO; Fareed J; Verrier ED
    J Heart Lung Transplant; 1993; 12(4):634-43. PubMed ID: 8396435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments.
    Fareed J; Kumar A; Walenga JM; Emanuele RM; Williamson K; Hoppensteadt D
    Nouv Rev Fr Hematol (1978); 1984; 26(4):267-75. PubMed ID: 6473096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is unfractionated heparin equivalent to low-molecular-weight heparin for venous thromboembolism?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2008 Jun; 77(11):1492-3. PubMed ID: 18581828
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy of a very low molecular weight heparin fragment (CY 222) compared to standard heparin in patients with deep venous thrombosis. A randomized study].
    Faivre R; Neuhart E; Kieffer Y; Bassand JP; Maurat JP
    J Mal Vasc; 1987; 12 Suppl B():145-6. PubMed ID: 2834488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enoxaparin (Clexane), a low molecular weight heparin in preventing thrombosis].
    Jørgensen LN; Hauch O
    Ugeskr Laeger; 1989 Nov; 151(48):3256-8. PubMed ID: 2556826
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and organ distribution in rats of a low molecular weight heparin.
    Guizzardi S; Mastacchi R; Govoni P; Milani MR; Barbanti M; Ruggeri A
    Arzneimittelforschung; 1987 Nov; 37(11):1281-3. PubMed ID: 2830892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Low-molecular-weight heparins].
    Rocha E; Páramo JA; Sarrá J
    Med Clin (Barc); 1993 Apr; 100(16):620-7. PubMed ID: 8388527
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.